Sugi Predict

Sugi Predict / Compounds / SCHEMBL21997364

SCHEMBL21997364

SCHEMBL21997364

CNC1CCN(Cc2ccc3c(c2)n(C)c(=O)n3C2CCC(=O)NC2=O)CC1

nearest known ligand 0.70

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 10/20 0.70
▸ DDB1 Q16531 8/20 0.70
▸ IKZF3 Q9UKT9 4/20 0.40
▸ IKZF2 Q9UKS7 5/20 0.39
▸ IKZF1 Q13422 2/20 0.38
▸ KCNH2 Q12809 2/20 0.38
▸ MCHR1 Q99705 2/20 0.38
▸ DRD2 P14416 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL30112403 0.92 CRBN (0.61) CRBNDDB1IKZF3IKZF2IKZF1
SCHEMBL24764683 0.89 CRBN (0.70) CRBNDDB1IKZF3IKZF2IKZF1
SCHEMBL21070327 0.89 CRBN (0.71) CRBNDDB1IKZF3IKZF2IKZF1
SCHEMBL23945676 0.89 CRBN (0.70) CRBNDDB1IKZF3IKZF2IKZF1
SCHEMBL30289114 0.88 CRBN (0.67) CRBNDDB1IKZF3IKZF2IKZF1
SCHEMBL21997980 0.87 CRBN (0.68) CRBNDDB1IKZF3IKZF2IKZF1
SCHEMBL21069482 0.87 CRBN (0.61) CRBNDDB1IKZF3IKZF2DRD2
SCHEMBL21107342 0.87 CRBN (0.61) CRBNDDB1IKZF3IKZF2DRD2
SCHEMBL24881180 0.86 CRBN (0.70) CRBNDDB1IKZF3IKZF2IKZF1
SCHEMBL25585838 0.86 CRBN (0.64) CRBNDDB1IKZF3IKZF2IKZF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 — — US disclosed
CN-119013277-A TYK2 degrading agent and application thereof 凯麦拉医疗公司 2024-11-22 — — CN disclosed
US-20240343733-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS C4 THERAPEUTICS, INC. 2024-10-17 — — US disclosed
EP-4423086-A1 TYK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-09-04 — — EP disclosed
EP-4405359-A2 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-31 — — EP disclosed
US-20220324854-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-13 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 — — EP disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 CRBN 39/4885DDB1 511/4885IKZF3 202/4885
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885IKZF3 135/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885IKZF3 135/4885
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A CRBN 111/4885DDB1 2403/4885IKZF3 208/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 CRBN 79/4885DDB1 2480/4885IKZF3 229/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885IKZF3 135/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885IKZF3 135/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885IKZF3 135/4885
US-20220324854-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885IKZF3 135/4885
US-20240343733-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS IRAK4, IRAK2, IRAK1 CRBN 193/4885DDB1 433/4885IKZF3 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.